Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Inhibrx Biosciences, Inc. (INBX) had Income from Continuous Operations of $-36.65M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-36.65M |
|
-- |
|
-- |
|
$32.15M |
|
$-32.15M |
|
$-4.50M |
|
$-36.65M |
|
$-36.65M |
|
$-36.65M |
|
|
Income from Continuous Operations |
$-36.65M |
$-36.65M |
|
$-36.65M |
|
$-32.15M |
|
$-31.63M |
|
15.67M |
|
15.67M |
|
$-2.34 |
|
$-2.34 |
|
| Balance Sheet Financials | |
$142.21M |
|
$2.69M |
|
$12.01M |
|
$154.22M |
|
$28.06M |
|
$176.28M |
|
$179.13M |
|
$207.20M |
|
$-52.98M |
|
$-52.98M |
|
$-52.98M |
|
14.71M |
|
| Cash Flow Statement Financials | |
$-67.94M |
|
$0.00M |
|
$77.07M |
|
$124.22M |
|
$133.34M |
|
$9.12M |
|
$5.76M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.07 |
|
-- |
|
-- |
|
1.43 |
|
-3.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-67.94M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
69.18% |
|
69.18% |
|
-23.76% |
|
-29.72% |
|
$-3.60 |
|
$-4.34 |
|
$-4.34 |
|